4,5-dibromo-1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-one

We are 4,5-dibromo-1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-one CAS:196597-77-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4,5-dibromo-1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-one
CAS.NO:196597-77-0
Synonyms:4,5-dibromo-1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-one
4,5-dibromo-1,2,6,7-tetrahydro-8H indeno[5,4-b]furan-8-one
8H-Indeno[5,4-b]furan-8-one,4,5-dibromo-1,2,6,7-tetrahydro
4,5-Dibromo-1,2,6,7-tertahydro-8H-indeno[5,4-b]furan-8-one
 
Physical and Chemical Properties:
Density 2.0±0.1 g/cm3
Boiling Point 448.6±45.0 °C at 760 mmHg
Melting Point 224-226ºC
Molecular Formula C11H8Br2O2
Molecular Weight 331.988
Flash Point 225.1±28.7 °C
 
Specification:
Appearance:Yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Ramelteon(CAS:196597-26-9).

4,5-dibromo-1,2,6,7-tetrahydrocyclopenta[e][1]benzofuran-8-one


Related News: Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.2-bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one CAS:283173-80-8 Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.79349-82-9 A key publication in a preclinical model demonstrated rigosertib’s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: “A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.” Cell 165, 643).N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline A key publication in a preclinical model demonstrated rigosertib’s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: “A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.” Cell 165, 643).“Administrative Measures for the Joint Review, Review and Approval of Raw Materials, Medicinal Auxiliaries and Pharmaceutical Packaging Materials and Pharmaceutical Preparations” (Consultation Draft) issued by the State Food and Drug Administration in December 2017. Supervision departments no longer accept applications for registration of APIs, pharmaceutical excipients, and packaging materials.

Related Products
Product Name
N-Cbz-L-4-Hydroxyproline methyl ester View Details
3-(tert-Butyldimethylsilyloxy)glutaric anhydride View Details
2-Amino-5-bromopyridine View Details
2-((1-Benzylpiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one manufacturer 5-hydroxymethyl Tolterodine manufacturer 5-Fluoro-2-methyl-3-nitrobenzoic acid manufacturer 2-Chloro-5-iodobenzoic acid manufacturer ETHYL THIOBUTYRATE manufacturer